Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Euretos joins HollandBIO as it’s first AI technology providerFriday 16 February 2018
This week, Euretos joined HollandBIO, the leading privately funded interest group of Dutch biotech companies representing over 170 life sciences companies in the Netherlands. 'Euretos is a great addition to the HollandBIO member base as its f ...
Elsevier and Euretos start innovative pilot to bring AI-derived hypotheses into the scholarly dialogueTuesday 06 February 2018
Amsterdam, February 6, 2018 – Elsevier, the information analytics business specializing in science and health, and Euretos announced a joint pilot to enrich scientific publications with hypotheses that are generated using the Euretos AI Platform. ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.